Secuencia de perfusión arterial reversa gemelar (TRAP). Reporte de caso clínico de manejo expectante

  1. Maita Quispe, Freddy 1
  2. Alí , Reynaldo
  3. Valdivieso , Luis
  1. 1 Universidad Mayor de San Simón
    info

    Universidad Mayor de San Simón

    Cochabamba, Bolivia

    ROR https://ror.org/03z27es23

Revue:
Gaceta Médica boliviana

ISSN: 1012-2966,  2227-3662

Année de publication: 2020

Titre de la publication: GACETA MEDICA BOLIVIANA

Volumen: 43

Número: 2

Pages: 228-231

Type: Article

DOI: 10.47993/GMB.V43I2.180 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

D'autres publications dans: Gaceta Médica boliviana

Résumé

TRAP describes the chronic perfusion of an "acardiac" twin by a "pump" twin through permeable interlocking vascular channels. TRAP occurs in 1 in 35,000 births or 1 in 100 pairs of monozygotic twins. It is diagnosed by ultrasound findings of a normally developing fetus and an amorphous mass often with noticeable fetal parts. Color Doppler reveals the reverse blood flow to the acardiac twin within the umbilical artery, leading to typical complications of the condition. Expectant management is reasonable in the absence of poor prognostic characteristics. The purpose of this article is to review the basic aspects and current status of this condition, emphasizing the diagnosis and expectant management.

Références bibliographiques

  • -Garcia M MN, Binefa G, Benito L, Gonzalo N, Moreno V. Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: are we there yet? Eur J Cancer Prev. 2015;24(4):321-7.
  • Jover R CF, Ponce M, Pérez-Riquelme F, Salas D, Cruzado-Quevedo J, Sala T, Torrella E, Zapater P. El Test De Sangre Oculta En Heces InmunolÓgico Es Mas Coste-Efectivo Que El Guayaco. Comparacion Entre Dos Programas De Cribado Poblacional De CÁncer Colorrectal. Gastroenterología y Hepatología. 2009;32(3):230.
  • Manz M BE, Rothen C. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterology. 2012;12(5):1-9.
  • Pieczarkowski S K-DK, Kwinta P, et al. Diagnostic Value of Fecal Calprotectin (S100 A8/A9) Test in Children with Chronic Abdominal Pain. Gastroenterol Res Pract. 2016;2016:8089217.
  • Burri E BC. The use of fecal calprotectin as a biomarker ingastrointestinal disease. Expert Rev Gastroenterol Hepatol 2014;8(2):197-210.
  • Siddiqui I MH, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther. 2017;8(1):39-46.
  • Manouchehr K, Pishahang P, Mohammad N, Alireza L, Mahasti A, RN. M. Diagnostic Value of Fecal Calprotectin as a Screening Biomarker for Gastrointestinal Malignancies. Asian Pacific Journal of Cancer Prevention. 2014;15(4):1667-70.
  • Stephen B HM. The Use of Fecal Calprotectin in Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2017;13(1).
  • Manz M BE, Rothen C, Nuschin T, changuizi N, Niederberger C, et al. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterology. 2012;12:1-9.
  • Lozoya M E dLHGI, Martinez M, Noguera JA, Aviles F. Faecal calprotectin, an useful marker in discriminating between inflammatory bowel disease and functional gastrointestinal disorders. Gastroenterol Hepatol. 2017;40(3):125-31.
  • D’Haens G FM, Vermeire S, Baert F, Noman M, et l. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(12):2218-24.
  • Tibble G SR, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402- 8.
  • Widlak MM TC, Thomas MG, et al. Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients. Aliment Pharmacol Ther. 2017;45(2):354-63.
  • Turvill J AA, Sivarajasingham N, et al. Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study. Br J Gen Pract. 2016;66(648):e499-506.
  • kok L SE, et al. . Diagnostic Accuracy of Point- of- Care Fecal Calprotectin and Immunochemical Occult Blood Tests for Diagnosis of Organic Bowwel Disease in Primary Care: The Cost - Effectivaness of a Dicision Rule for Abdominal Complaints in Primary Care (CEDAR) Study. Clinical Chemistry. 2012;58:989-98.
  • Tibble J SG, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Published by groupbmjcom. 2001;49:402–8.
  • Lehmann FS, Trapani F, Fueglistaler I, Terracciano LM, von Flue M, Cathomas G, et al. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World J Gastroenterol. 2014;20(17):4994-9.
  • M. M. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World Journal of Gastroenterology. 2010;16(27):3406.
  • Egea J, Alberca F, Alvarez FJ, Estrella E ea. Calprotectina Fecal Como Predictor De Lesiones En Intestino Delgado Diagnosticadas Con CÁpsula EndoscÓpica. Endoscopy. 2014;46(11).
  • Valenzuela J AF, Carballo F. Calprotectina fecal como predictor de lesiones inflamatorias en intestino delgado diagnosticadas con cápsula endoscópica. Revista Española de Enfermedades Digestivas. 2015;107:211-5,.
  • García M GR, Iglesias E, Gómez F , Juanena L, Cerezo A. Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica. Med Clinic. 2006;127:41-6.
  • Burri E MM, Rieder S, Beglinger C. Limited value of fecal calprotectin in patients with liver cirrhosis. Scand J Gastroenterol. 2011;46(12):1527-8.
  • Montalto M. Can chronic gastritis cause an increase in fecal calprotectin concentrations? World Journal of Gastroenterology. 2010;16(27):3406.
  • AL. GSME. Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica. Med Clin (Barc). 2006;127 (2):41-6.
  • Lehmann FS TF, Fueglistaler I,Terracciano LM, von Flue M, et al. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World J Gastroenterol. 2014;20(17):4994-9.
  • van Rheenen PF VdVE, Fidler V, . Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
  • Mooiweer E et al. Fecal hemoglobin and calprotectin ar equally effectve in identifying patients with active endoscopic inflammation: Oxdord academic. 2014;20(2):307-314.
La source de données: Dialnet